Treats hypertension. ANDA 90534, held by Am Regent. Nicardipine Hydrochloride.
As of Nov 22, 2026, ANDA 90534 (Nicardipine Hydrochloride), held by Am Regent, was first approved by FDA on Nov 17, 2009, with 2 approved supplements and 0 published complete response letters.
1. INDICATIONS AND USAGE niCARdipine hydrochloride injection is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 17, 2009 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nicardipine Hydrochloride25MG/10ML (2.5MG/ML) · injectable;injection | Nicardipine Hydrochloride | Rx |
| Jun 2, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 2, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 17, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters